Recommended Articles
Fundraising

WhiteLab Genomics Closes $26M Series B to Scale AI-Designed Genetic Medicines

By Angeled · October 7, 2026 · Fundraising
WhiteLab Genomics Closes $26M Series B to Scale AI-Designed Genetic Medicines
WhiteLab Genomics Closes $26M Series B to Scale AI-Designed Genetic Medicines

The WhiteLab Genomics Series B is a bet on solving AI drug design's hardest problem: not designing molecules, but knowing which designs work inside a living body. On October 6, 2026, the Paris-based company — with operations also in Boston and Montreal — announced a $26 million (€23.2 million) Series B led by AVP. New investors Yaday Health and Blast Club joined existing backers Omnes Capital and Debiopharm Innovation Fund. The round brings total funding to approximately $37 million.

What WhiteLab Genomics Builds

WhiteLab Genomics' ALFRED platform uses AI to design delivery vehicles — both viral and non-viral — and programmable genetic payloads for genomic medicines. Where most AI drug-design companies stop at the in silico stage, WhiteLab then tests its designs experimentally and in vivo, closing the loop between prediction and biological reality.

The company says that is the real differentiator. The commercial bottleneck in AI drug design is not generating candidate designs; it's knowing which designs behave correctly in a living system. Delivery is the crux of the entire genomic-medicine field — a perfect genetic payload is useless if it can't reach the right cells.

Early Data: Blood-Brain Barrier in Animals

According to the company, AI-designed AAV candidates developed with the Paris Brain Institute crossed the blood-brain barrier in animal studies with a strong brain-to-liver targeting ratio and no detectable liver signal. That's a meaningful preclinical result — getting gene therapies into the brain while avoiding the liver (a common off-target sink that raises safety concerns) is one of the field's central challenges.

Important caveat: this is preclinical, animal data, not human evidence. Plenty of candidates that look promising in animals fail in humans. But for investors, the signal is the platform's design-test loop working as advertised.

Why the WhiteLab Genomics Series B Matters for Founders and Investors

For founders: WhiteLab's story is a masterclass in differentiation within a crowded space. "AI for drug design" is one of the most saturated pitches in venture. WhiteLab didn't pitch better models — it pitched the missing piece everyone else outsources: experimental and in vivo validation of AI-designed candidates. If you're building in a crowded AI category, the lesson is to own the bottleneck your competitors leave unsolved.

For investors: The ~15 revenue-generating partnerships with biotech and pharma — including Sanofi, per Axios reporting cited in the announcement — are the real tell. Revenue-generating partnerships mean the platform is being paid to prove itself before the company's own pipeline matures. For a $37M-total-funded company, that's efficient capital discipline: the platform pays for its own de-risking. The watch item is straightforward — can ALFRED-derived candidates move from animal studies toward human trials, and do the partnerships expand or churn?

Angeled.com connects founders with investors.

Read Next